1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Hub24 (ASX:HUB) achieved record platform net inflows of $18.9 billion in FY26, up 20% on the prior year... taking its funds under administration to $164.3 billion. Fourth-quarter platform inflows were $4.2 billion, while platform assets rose 24 per cent to $139.5 billion, driven by growth in advisers and positive market movements. Hub24 said structural demand for financial advice, compulsory superannuation and proposed tax changes support its growth outlook, while new retirement products and AI-powered initiatives were expected to underpin further expansion.
Plenti (ASX:PLT) has achieved record quarterly loan originations of $536 million, up 22% on the previous corresponding period. Its loan portfolio increased 23% to $3.3 billion on the previous year, while revenue came in at $84.6 million over the same period.
Change Financial (ASX:CCA) delivered US$4.6 million revenue and underlying EBITDA of US$800 thousand in the furth quarter of FY26. The company says it expects strong momentum to continue in its Australian and NZ platform as a service businesses.
Telix Pharmaceuticals (ASX:TLX) has seen second-quarter revenue increase 21% to $US247 million with it heading to meet the upper end of its full-year sales guidance. Precision medicine revenue rose 30%, while the company expects FY26 revenue of between $US950 million to $US970 million, plus $US40 million in non-refundable income from Regeneron, taking total revenue and other income to more than US$1 billion.
Clinuvel Pharmaceuticals’ (ASX:CUV) American Depositary Shares have begun trading on the Nasdaq, completing the biotech's upgrade of its US listing. This gives Clinuvel a full Nasdaq listing while maintaining its primary listing on the ASX.
AFT Pharmaceuticals (ASX:AFP) has received tentative approval from the US Food and Drug Administration for its drug Scomara to treat Facial Angiofibromas. The drug affects up to 30,000 patients in the US. However, the US launch is delayed until at least March 2029 due to existing orphan exclusivity held by another product. AFT says it will pursue markets including Canada, Australia, New Zealand, and Asia, where the orphan exclusivity does not apply.
Data centre operator NEXTDC (ASX:NXT) has lifted its contracted utilisation by 73 megawatts to 740 megawatts following further customer contract wins. The company's forward order book has increased to 565 megawatts as of the end of June. It's maintaining its FY26 guidance for net revenue, underlying EBITDA and capital expenditure.
New Zealand's Contact Energy (ASX:CEN) lifted its mass market electricity and gas sales to 495 gigawatt hours in June 2026... from 410 gigawatt hours a year earlier. It says it is advancing four renewable projects totalling 1.5 billion dollars, with Kōwhai Park Solar and Glorit Solar expected online in the coming years.
Alkane Resources (ASX:ALK) delivered record production in FY26 of 168 thousand ounces of gold equivalent, while meeting its cost guidance with all-in sustaining costs of 2,907 dollars per ounce. The company reported $174 million in operating cash flows during the June quarter, and its proposed a fully franked dividend of 2 cents per share.
